)
SIGNIFICANT REDUCTION AT WEEK 24 AND WEEK 52 IN NPS WITH DUPIXENT1,2
61%
Improvement
in nasal polyp burden with DUPIXENT vs 15% with placebo,
-3.16 from a baseline score of 5.12 with DUPIXENT (n=33) at Week 24 (secondary endpoint) vs
-0.80 from a baseline score of 5.38 with placebo (n=29); LSM difference: -2.36 (95% CI: -3.31, -1.41) (P<0.0001)1,2
63%
Improvement
in nasal polyp burden with DUPIXENT vs 4% with placebo,
-3.32 from a baseline score of 5.12 with DUPIXENT (n=33) at Week 52 (secondary endpoint) vs
-0.55 from a baseline score of 5.38 with placebo (n=29); LSM difference: -2.77 (95% CI: -3.82, -1.72) (P<0.0001)1,2
Nasal polyp score (NPS): NPS is the sum of right and left nostril scores, as evaluated by nasal endoscopy. Maximum score is 4 for each nostril,
or 8 in total. Lower score indicates improvement (reduced polyp burden).1
LSM, least squares mean.